| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...871266B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0071266 |
| P932 | PMC publication ID | 3743865 |
| P698 | PubMed publication ID | 23967177 |
| P5875 | ResearchGate publication ID | 256072865 |
| P50 | author | Karthika Natarajan | Q59685417 |
| P2093 | author name string | Maria R Baer | |
| Suresh V Ambudkar | |||
| Mariola Sadowska | |||
| Suneet Shukla | |||
| Trevor J Mathias | |||
| Jasjeet Bhullar | |||
| P2860 | cites work | Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance | Q26865927 |
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| Prognostic relevance of integrated genetic profiling in acute myeloid leukemia | Q27851726 | ||
| Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells | Q32016277 | ||
| Drug-induced prolongation of the QT interval | Q33151147 | ||
| The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype | Q33243645 | ||
| Biochemical, cellular, and pharmacological aspects of the multidrug transporter | Q33636699 | ||
| Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 | ||
| P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 | Q34124919 | ||
| VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein | Q34304819 | ||
| Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 | Q34360283 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
| Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. | Q34637551 | ||
| Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse | Q34754344 | ||
| Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout | Q34985649 | ||
| Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein | Q35076190 | ||
| ABC of oral bioavailability: transporters as gatekeepers in the gut. | Q35591517 | ||
| Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. | Q52828279 | ||
| Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias | Q58290358 | ||
| Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells | Q71094131 | ||
| Regulation of ciprofloxacin uptake in human promyelocytic leukemia cells and polymorphonuclear leukocytes | Q73292917 | ||
| Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers | Q73563720 | ||
| ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia | Q83895091 | ||
| Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction | Q84124203 | ||
| Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition | Q94705289 | ||
| Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies | Q35817464 | ||
| Collateral sensitivity as a strategy against cancer multidrug resistance | Q35946556 | ||
| Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance | Q35946822 | ||
| Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia | Q36366636 | ||
| Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. | Q36496944 | ||
| Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system | Q36610461 | ||
| The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2 | Q36933169 | ||
| Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. | Q37188016 | ||
| AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) | Q37373040 | ||
| Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties | Q37447522 | ||
| Bench to bedside targeting of FLT3 in acute leukemia | Q37724957 | ||
| Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? | Q37853578 | ||
| Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia | Q38011962 | ||
| FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations | Q39513601 | ||
| Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation | Q39747662 | ||
| Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. | Q39944267 | ||
| Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. | Q40118559 | ||
| The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. | Q40254927 | ||
| Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion | Q40325508 | ||
| Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia | Q40442997 | ||
| Cyclosporin A is a broad-spectrum multidrug resistance modulator | Q40443016 | ||
| Gefitinib reverses breast cancer resistance protein-mediated drug resistance | Q40515752 | ||
| Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function | Q40543176 | ||
| FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells | Q40635369 | ||
| Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line | Q40907899 | ||
| Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. | Q40968389 | ||
| Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state | Q41043571 | ||
| Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates | Q42497379 | ||
| Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells | Q42827076 | ||
| P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor | Q42952483 | ||
| European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy | Q43102335 | ||
| Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse | Q43797937 | ||
| Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. | Q44083625 | ||
| Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. | Q44189526 | ||
| Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources | Q44578925 | ||
| The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors | Q45072250 | ||
| Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias | Q45178457 | ||
| Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. | Q46531521 | ||
| The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | Q46580597 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| quizartinib | Q7272714 | ||
| P304 | page(s) | e71266 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions | |
| P478 | volume | 8 |
| Q39049159 | ABCG2/BCRP: Specific and Nonspecific Modulators. |
| Q41943341 | Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. |
| Q41172549 | Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia |
| Q54977469 | Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization. |
| Q35940547 | Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. |
| Q92485655 | Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports |
| Q48263650 | Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. |
| Q47139045 | Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies |
| Q33688129 | Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2 |
| Q48371869 | The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations |
Search more.